Nu-Med Plus, Inc.
Nu-Med Plus, Inc. (NUMD) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Nu-Med Plus, Inc. (NUMD), featuring income statements, balance sheets, and cash flow data.
Nu-Med Plus, Inc. (NUMD) Income Statement & Financial Overview
Explore comprehensive income reports for Nu-Med Plus, Inc. NUMD, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $600.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $300.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $300.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.50 | $0.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $10419.00 | $18700.00 | $9294.00 | $17417.00 |
| Operating Expenses | $10419.00 | $18700.00 | $9294.00 | $17417.00 |
| Total Costs & Expenses | $10419.00 | $18700.00 | $9294.00 | $17417.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1246.00 | $1233.00 | $1261.00 | $1260.00 |
| Depreciation & Amortization | $0.00 | $18700.00 | $9294.00 | $17417.00 |
| EBITDA | -$10419.00 | -$18700.00 | -$9294.00 | -$17417.00 |
| EBITDA Ratio | $0.00 | $0.00 | -$15.49 | $0.00 |
| Operating Income | -$10419.00 | -$18700.00 | -$9294.00 | -$17417.00 |
| Operating Income Ratio | $0.00 | $0.00 | -$15.49 | $0.00 |
| Other Income/Expenses (Net) | -$1246.00 | -$1233.00 | -$1261.00 | -$1260.00 |
| Income Before Tax | -$11665.00 | -$19933.00 | -$10555.00 | -$18677.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | -$17.59 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11665.00 | -$19933.00 | -$10555.00 | -$18677.00 |
| Net Income Ratio | $0.00 | $0.00 | -$17.59 | $0.00 |
| EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| Diluted EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| Weighted Avg Shares Outstanding | $83.55M | $83.55M | $83.55M | $81.35M |
| Weighted Avg Shares Outstanding (Diluted) | $83.55M | $83.55M | $83.55M | $81.35M |
Financial performance has remained strong, with revenue growing from $0.00 in Q3 2024 to $0.00 in Q2 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$10419.00 in Q2 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$10419.00. Net income rose to -$11665.00, keeping EPS at -$0.00. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan